Denis Patrick
Private Equity Investor at PFIZER, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jim Broderick | M | 55 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 9 years |
Albert Bourla | M | 62 | 31 years | |
Stephen Worland | M | 66 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 12 years |
Frank G. Haluska | M | 64 |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
Douglas Lankler | M | 58 | 25 years | |
Colin Goddard | M | 64 |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 9 years |
Sue Desmond-Hellmann | M | 66 | 4 years | |
Stephen Philip Jackson | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 13 years |
Alana McNulty | F | 61 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 12 years |
Hugo Beekman | M | - |
Evolveimmune Therapeutics, Inc.
Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | - |
Michael Baran | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 16 years |
James Quincey | M | 59 | 4 years | |
Joseph Echevarria | M | 66 | 9 years | |
Dan Littman | M | 71 | 6 years | |
Sotirios K. Sotiriou | M | - |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | 5 years |
John Hennessy | M | - |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | - |
Rady Johnson | M | 63 | 30 years | |
Alessandra di Bacco | F | - |
Evolveimmune Therapeutics, Inc.
Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | - |
Thanos Halazonetis | M | - |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | 5 years |
Margaret M. Madden | F | - | - | |
Rana Al-Hallaq | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
Christopher O’Donnell | M | 55 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 6 years |
David Johnson | M | 59 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 3 years |
Eyal Gottlieb | M | - |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | 11 years |
Helen Hobbs | M | 71 | 13 years | |
James B. Summers | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 5 years |
Jim Smith | M | 64 | 10 years | |
Stephen Bloch | M | 62 |
Evolveimmune Therapeutics, Inc.
Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | 4 years |
Sally Susman | F | 62 | 17 years | |
Anker Gunvald Lundemose | M | 63 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Ronald Blaylock | M | 64 | 7 years | |
Barbara Dalton | M | 69 |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 17 years |
Shantanu Narayen | M | 60 | 11 years | |
Michael G. Moore | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 12 years |
Deepa Pakianathan | M | 59 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 4 years |
Susan Hockfield | M | 73 | 4 years | |
Suzanne Johnson | F | 66 | 17 years | |
Scott Gottlieb | M | 51 | 5 years | |
John DeYoung | M | 61 | 33 years | |
Jeff Settleman | M | - | 5 years | |
Markus Green | M | - | 18 years | |
Johannes Zanzinger | M | - |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | - |
Mike McDermott | M | 58 | 21 years | |
Gordon Loh | M | - | 4 years | |
Annaliesa Anderson | M | - | 17 years | |
Avery Waite | F | - | 1 years | |
Aamir Malik | M | 48 | 3 years | |
Patrice Ettinger | F | - | - | |
Payal Sahni Becher | F | - | 27 years | |
Jon Root | M | 64 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | - |
Noga Yerushalmi | F | - |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | - |
Mikael Dolsten | M | 65 | 15 years | |
David Aviezer | M | 59 |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | - |
Bryan Supran | M | - | 8 years | |
Carole Nüchterlein | F | 62 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 7 years |
Lidia Fonseca | F | 55 | - | |
Dave Maki | M | - |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 9 years |
Simeon George | M | 47 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 11 years |
John Smither | M | 71 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | 6 years |
Irena Melnikova | M | - |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | 2 years |
Lori Hu | F | 38 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | 6 years |
Larry Lasky | M | 73 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | - |
Brian Gallagher | M | 54 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | - |
Chris Boshoff | M | - | - | |
Karan Takhar | M | 32 |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | - |
Jennifer Damico | F | 56 | 4 years | |
Stefan Mathias Larson | M | 48 |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | - |
David Luther | M | - |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 9 years |
Suneet Varma | M | 55 | 23 years | |
Aaron Foster | M | - | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
William Steere | M | 88 | 28 years | |
Ian Read | M | 71 | 41 years | |
Jeffrey Kindler | M | 68 | 8 years | |
George A. Lorch | M | 82 | 15 years | |
Amy Schulman | F | 63 | 6 years | |
Dennis Ausiello | M | 78 | 13 years | |
David Vurgait | M | 59 |
University of Pennsylvania
| 1 years |
John Mascotte | M | 84 | 4 years | |
Scott M. Gallin | M | 51 |
University of Pennsylvania
| 5 years |
John W. Glomb | M | - |
University of Pennsylvania
| 12 years |
Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 years |
Helen Remeza | M | - |
University of Pennsylvania
| 5 years |
Shiv Vikram Khemka | M | 61 |
University of Pennsylvania
| 2 years |
Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 years |
Yi Ning Zhao | M | 53 | 8 years | |
Jennifer Schroeder | F | - | 20 years | |
Joseph Arena | M | 69 | 3 years | |
Alex Abell | M | - |
University of Pennsylvania
| 4 years |
Olivier Brandicourt | M | 68 | 13 years | |
Marc Tessier-Lavigne | M | 64 | 4 years | |
Robert Landry | M | 60 | 4 years | |
Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 years |
Lisa Granick | F | - |
University of Pennsylvania
| 2 years |
Stephen W. Sanger | M | 78 | 9 years | |
Michael Brown | M | 83 | 16 years | |
Robert N. Burt | M | 86 | 11 years | |
Frances Fergusson | M | 79 | 9 years | |
Charles H. Hill | M | 69 | 31 years | |
Freda Lewis-Hall | M | 69 | 11 years | |
Lori McNeill | F | 51 | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 87 | 87.00% |
United Kingdom | 7 | 7.00% |
Israel | 4 | 4.00% |
Switzerland | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Denis Patrick
- Personal Network